β Home
βΉοΈ Info
π§Ύ At a Glance π Core Facts ποΈ Products/Services β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π Insights (7) π’ Company Q&A (663) π οΈ Industry Q&A (164) π Competitors π Price Low π Price Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risk Assessment π§© Segmentation π Ά Google Linksπ Ratios
π° Margins π Financial Ratios π± Growth π Enterprise Value π Key Metrics π΅ Dividendsπ§ Tools
β Due Diligenceπ₯ Video Insights
EBOS Group has been crushed. At around A$15.35, the shares are sitting near their 52-week low of A$15.37 and are roughly 43% below the previous high. Yet the underlying business continues to grow. Is the market overlooking what could become a powerful recovery story? First-half fiscal 2026 revenue increased 13% to A$6.77 billion, while underlying earnings before interest, tax, depreciation and amortisation rose 3.2% to A$300 million. Statutory profit increased 13% to A$126.6 million. Management expects stronger cash flow from fiscal 2027 as major capital investment winds down. The problem is profitability. Underlying net profit declined 4.3% in the first half, reflecting investment costs and pressure within the healthcare segment. Investors are also concerned about leverage, capital spending and the competitive pharmacy environment. The dividend provides another reason to watch the stock. EBOS paid 57 New Zealand cents per share for the 2026 interim dividend, while the previous full-year payment was 118.5 cents. The value case is compelling if earnings growth accelerates as investment spending falls. The main risks are thin margins, competitive pressure, debt and weaker consumer spending in animal care. A recovery could be substantial if cash flow improves and margins expand from fiscal 2027. This review is for informational and educational purposes only, not financial advice.
EBOS Group operates behind the scenes of the healthcare industry, distributing pharmaceuticals, medical products, and animal care solutions across Australia and New Zealand. In this video, we break down why the stock price has weakened recently, what the latest earnings reveal, how the companyβs dividends and margins are evolving, and whether this healthcare giant could recover in the coming years. InsightfulValue delivers clear, practical analysis of undervalued companies for both beginner and experienced investors. Subscribe for more stock analysis videos and deeper research and hidden value opportunities.
EBOS Groupβs stock has softened recently, slipping from prior highs as investors reassess growth expectations. The current price reflects caution rather than a deterioration in fundamentals. Recent results show steady revenue growth, supported by resilient demand, while earnings remain stable but not accelerating. Margins are relatively thin but consistent, typical for the sector, and cash generation remains strong. Dividends have been reliable and gradually increasing, offering a stable income component. The decline is driven by lower growth expectations, integration of past acquisitions, and broader market sentiment toward defensive names. From a value perspective, the stock may now appear more attractive due to its stability and predictable cash flows. However, risks include limited margin expansion and slower earnings growth. The bull case is continued steady performance and gradual improvement. The bear case is prolonged stagnation. This review is for informational and educational purposes only, not financial advice.
A quick, clear look at why EBOS Group shares have dropped: contract loss, profit drop, but still diversified operations. Is this a value opportunity or a risk zone?
In this video, we analyze EBOS Group, a leading healthcare distributor in Australasia, whose stock price has recently declined. We examine the companyβs financial performance, dividend history, and the factors contributing to the stockβs downturn. Join us as we explore whether EBOS Group presents an investment opportunity or if caution is warranted.
